{
    "clinical_study": {
        "@rank": "72141", 
        "arm_group": {
            "arm_group_label": "Transcranial Magnetic Stimulation (TMS)", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.\nEfficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and effectiveness of acute NeuroStar TMS\n      therapy in women who have postpartum depression."
        }, 
        "brief_title": "Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Depression, Postpartum", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Depressive Disorder, Major", 
                "Depression, Postpartum"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in\n      patients with MDD with postpartum onset.\n\n      Determine the safety of NeuroStar TMS Therapy by assessment of any medically significant,\n      device-related adverse events during acute treatment.\n\n      Determine the Safety of NeuroStar TMS Therapy by assessment of maternal and infant\n      interactions on standardized bonding questionnaires."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female outpatients, 18 to 50 years of age.\n\n          -  Diagnosis of DSM-IV defined Major Depressive Disorder, single or recurrent episode,\n             with current episode duration of at least 2 weeks.\n\n          -  Onset and duration of current illness within 6 months of live childbirth.\n\n          -  HAMD17 total score of greater than or equal to 18  and a score on the Edinburgh\n             Postnatal Depression scale (EPDS) greater than or equal to 10.\n\n          -  Patient cannot be on an antidepressant or other psychotropic medications during the\n             study.\n\n          -  Capable and willing to provide informed consent.\n\n          -  Signed HIPAA authorization.\n\n          -  Able to adhere to the treatment schedule.\n\n        Exclusion Criteria:\n\n          -  Individuals diagnosed by the Investigator with the following conditions (current\n             unless otherwise stated): Depression secondary to a general medical condition, or\n             substance-induced Seasonal pattern of depression as defined by DSM-IV;History of\n             substance abuse or dependence within the past year(except nicotine and caffeine);Any\n             psychotic disorder (lifetime), including schizoaffective disorder, or major\n             depression with psychotic features in this or previous episodes;Bipolar\n             disorder;Eating disorder (current or within the past year);Obsessive compulsive\n             disorder (lifetime); or Post-traumatic stress disorder (current or within the past\n             year).\n\n          -  Individuals with a clinically defined neurological disorder or insult including, but\n             not limited to:Any condition likely to be associated with increased intracranial\n             pressure;Space occupying brain lesion;History of cerebrovascular accident;Transient\n             ischemic attack within two years; Cerebral aneurysm; Dementia;Parkinson's\n             disease;Huntington's chorea;Multiple sclerosis.\n\n          -  History of treatment with Vagus Nerve Stimulation.\n\n          -  History of failure to respond to an adequate course of ECT treatment.\n\n          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute,\n             unstable cardiac disease.\n\n          -  Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants,\n             or electrodes) or any other metal object within or near the head, excluding the\n             mouth, that cannot be safely removed.\n\n          -  Women of child-bearing potential not using a medically accepted form of contraception\n             when engaging in sexual intercourse."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842542", 
            "org_study_id": "44-03014-000"
        }, 
        "intervention": {
            "arm_group_label": "Transcranial Magnetic Stimulation (TMS)", 
            "description": "Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.\n3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician.", 
            "intervention_name": "NeuroStar Transcranial Magnetic Stimulation (TMS)", 
            "intervention_type": "Device", 
            "other_name": "NeuroStar TMS Therapy Treatment"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Postpartum Depression, NeuroStar TMS Therapy, TMS", 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sherri.post@hhchealth.org", 
                    "last_name": "Sherri Post", 
                    "phone": "860-545-7476"
                }, 
                "facility": {
                    "address": {
                        "city": "Hartford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06102"
                    }, 
                    "name": "Hartford Hospital Institute of Living"
                }, 
                "investigator": {
                    "last_name": "John Goethe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dmason@ufl.edu", 
                    "last_name": "Dana Mason", 
                    "phone": "352-273-8540"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32606"
                    }, 
                    "name": "UF Health Adult Psychiatry - Springhill"
                }, 
                "investigator": {
                    "last_name": "Richard Holbert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "mgradia@harmonex.us", 
                    "last_name": "Morgan Gradia", 
                    "phone": "850-433-1656", 
                    "phone_ext": "17"
                }, 
                "facility": {
                    "address": {
                        "city": "Pensacola", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32502"
                    }, 
                    "name": "Harmonex Neuroscience and Research of Pensacola"
                }, 
                "investigator": {
                    "last_name": "Cris Jagar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33613"
                    }, 
                    "name": "University of South Florida-College of Medicine"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "Tara_Thomas@rush.edu", 
                    "last_name": "Tara Thomas", 
                    "phone": "312-942-7272"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Rado, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40222"
                    }, 
                    "name": "Integrative Psychiatry"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10022"
                    }, 
                    "name": "TMS Medical Associates of NY"
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Weill Cornell Medical College"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "vgillen@lehighcenter.com", 
                    "last_name": "Vince Gillen", 
                    "phone": "610-820-0343"
                }, 
                "contact_backup": {
                    "email": "lmuffley@lehighcenter.com", 
                    "last_name": "Leanne Muffley", 
                    "phone": "610.820.0342"
                }, 
                "facility": {
                    "address": {
                        "city": "Allentown", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18104"
                    }, 
                    "name": "TMS Center of Lehigh Valley"
                }, 
                "investigator": {
                    "last_name": "Paul Gross, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Penn-Penn Center for Women's Behavioral Wellness"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84108"
                    }, 
                    "name": "University of Utah - Neuropsychiatric Institute"
                }, 
                "status": "Terminated"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.", 
        "other_outcome": {
            "description": "Patients complete questionnaires during the acute and taper treatment phase at protocol specific timepoints.", 
            "measure": "Determine the safety of NeuroStar TMS Therapy by assessment of maternal and infant interactions on standardized bonding questionnaires.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 weeks plus 3 week taper."
        }, 
        "overall_contact": {
            "email": "dlchristie@neuronetics.com", 
            "last_name": "Darlene Lambert-Christie", 
            "phone": "610-981-4122"
        }, 
        "overall_contact_backup": {
            "email": "awaltman@neuronetics.com", 
            "last_name": "Angela Waltman", 
            "phone": "610-981-4139"
        }, 
        "overall_official": {
            "affiliation": "Neuronetics, Inc.", 
            "last_name": "David Brock, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Acute NeuroStar TMS treatment of 5 days per week for upto 8 weeks.", 
            "measure": "Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in patients with MDD with postpartum onset", 
            "safety_issue": "Yes", 
            "time_frame": "up to 8 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842542"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Medically significant, device related adverse events will be collected during the acute and taper phase.", 
            "measure": "Determine the safety of NeuroStar TMS Therapy.", 
            "safety_issue": "Yes", 
            "time_frame": "upto 8 weeks plus 3 week taper."
        }, 
        "source": "Neuronetics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neuronetics", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}